Your browser doesn't support javascript.
loading
Anticipating New Treatments for Cystic Fibrosis: A Global Survey of Researchers.
Cabral, Bernardo; Terlizzi, Vito; Laselva, Onofrio; Conte Filho, Carlos; Mota, Fabio.
Afiliación
  • Cabral B; Department of Economics, Federal University of Bahia, Salvador 40060-300, Brazil.
  • Terlizzi V; Cystic Fibrosis Regional Reference Center, Department of Paediatric Medicine, Anna Meyer Children's University, 50139 Florence, Italy.
  • Laselva O; Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
  • Conte Filho C; Department of Economics, Federal University of Santa Maria, Santa Maria 97105-900, Brazil.
  • Mota F; Laboratory of Cellular Communication, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-360, Brazil.
J Clin Med ; 11(5)2022 Feb 26.
Article en En | MEDLINE | ID: mdl-35268374
Cystic fibrosis is a life-threatening disease that affects at least 100,000 people worldwide. It is caused by a defect in the cystic fibrosis transmembrane regulator (CFTR) gene and presently, 360 CFTR-causing mutations have been identified. Since the discovery of the CFTR gene, the expectation of developing treatments that can substantially increase the quality of life or even cure cystic fibrosis patients is growing. Yet, it is still uncertain today which developing treatments will be successful against cystic fibrosis. This study addresses this gap by assessing the opinions of over 524 cystic fibrosis researchers who participated in a global web-based survey. For most respondents, CFTR modulator therapies are the most likely to succeed in treating cystic fibrosis in the next 15 years, especially through the use of CFTR modulator combinations. Most respondents also believe that fixing or replacing the CFTR gene will lead to a cure for cystic fibrosis within 15 years, with CRISPR-Cas9 being the most likely genetic tool for this purpose.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2022 Tipo del documento: Article País de afiliación: Brasil

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2022 Tipo del documento: Article País de afiliación: Brasil